SCHEMBL2653616

SCHEMBL2653616

CCNC(=O)COC(=O)c1ccc2c(c1)ncn2-c1cccc(N2CCN(CCOCC)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.46
NPC1 O15118 2/20 0.46
FGFR1 P11362 1/20 0.44
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 8/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
RAB9A P51151 1/20 0.40
DRD3 P35462 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652367 0.93 FGFR1 (0.47) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL2652876 0.93 KMT2A (0.49) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL2653245 0.87 KMT2A (0.51) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL4701541 0.86 KMT2A (0.48) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL2654163 0.86 KMT2A (0.47) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL2653620 0.86 KMT2A (0.49) KMT2AMEN1NPC1FGFR1HPGD
SCHEMBL2652333 0.85 FGFR1 (0.54) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL2651654 0.85 FGFR1 (0.48) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL2653615 0.84 MAPK1 (0.48) KMT2AMEN1NPC1FGFR1MAPK1
SCHEMBL2652366 0.83 FGFR1 (0.47) KMT2AMEN1NPC1FGFR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP claimed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US claimed
EP-1615896-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2006-01-18 EP claimed
WO-2004089912-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2004-10-21 WO claimed
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP disclosed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US disclosed
EP-1615896-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2006-01-18 EP disclosed
WO-2004089912-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA2, GABRA1, GABRA5 KMT2A 2056/4885MEN1 4670/4885NPC1 3809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.